Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Aragon

- PMLiVE

Major prostate cancer screening trial launched in UK

The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

- PMLiVE

J&J’s Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis

The drug is the first IL-23 inhibitor approved for children from the age of six

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

FDA approves new presentation of Celltrion’s SteQeyma for paediatric psoriasis

The Stelara biosimilar now offers all dosage forms and strengths of its reference product

- PMLiVE

J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

- PMLiVE

Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

More than 2.5 million people in Europe are affected by the inflammatory bowel disease

- PMLiVE

Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

More than 2.5 million people in Europe are living with the inflammatory bowel disease

- PMLiVE

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

The inflammatory condition affects approximately 30% of psoriasis patients

- PMLiVE

J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

Approximately 25% of cases are diagnosed during childhood or adolescence

- PMLiVE

Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use

The authorisation approximately triples the number of patients eligible to receive the therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links